The FDA is currently reviewing Summit's PD-1/VEGF bispecific as part of a chemotherapy combo for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer.

With a phase 3 win for a combination of its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) and Keytruda, Merck & Co.’s partner Kelun-Biotech is the latest to claim that ...

The F.D.A. approved Merck’s injected version of its blockbuster infusion Keytruda. The company says it will be quicker and easier, but it stands to slow the adoption of cheaper competitors and ...

Represents the first PD-1 inhibitor plus ADC regimens for this patient population These approvals are based on data from the Phase 3 KEYNOTE-905 trial (also known as EV-303), which was conducted in ...

Summit Therapeutics Inc. (NASDAQ:SMMT), on Sunday, revealed the updated overall survival (OS) results from the global Phase 3 HARMONi trial of ivonescimab at the 2025 World Conference on Lung Cancer ...

– The First Pivotal Phase 3 Trial to Demonstrate Superiority of a TROP-2 Antibody-Drug Conjugate, Trodelvy, Plus Keytruda Versus Standard of Care Keytruda plus Chemotherapy in 1L mTNBC – – Trodelvy ...

Shared decision-making in ALK-positive NSCLC is crucial, with patient-authored guides aiding in managing lorlatinib side effects and empowering patients. Newly diagnosed lung cancer patients benefit ...